Blood-based transcriptional risk scores and Alzheimer’s disease

Takeaway

  • Blood-based transcriptional risk score (TRS) is significantly associated with Alzheimer’s disease (AD) diagnosis and neuroimaging markers.

Why this matters

  • Transcriptional risk scores, a computation of polarized expressed levels of functional genes reflecting disease risk, have been proposed and utilized to distinguish Crohn’s disease patients from healthy controls; however, this approach has not been applied to AD.

  • Identification of early, and easily accessible AD markers has important implications for early disease diagnosis and development of targeted therapies in high risk individuals, given the increasing prevalence of AD worldwide.